News

Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.

By embracing change, leveraging emerging trends and prioritizing patient-centered care, organizations and individuals can find opportunities for growth and innovation in the post-pandemic era.

Both Wyost and Jubbonti are interchangeable for the reference products and are approved for all of the same indications in osteoporosis and bone cancer.

Women experiencing high levels of poverty and those in impoverished rural regions are less likely to get screened for breast cancer, find a new review of studies that have assessed social determinants of health.

The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.

Hospitals and healthcare software developers are adjusting to a world in which blocking healthcare data will come with potentially stiff penalties under rules proposed by the Office of the National Coordinator for Health Information Technology (ONC).

Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.

Advances in MS disease management have included the emergence of monoclonal antibodies as effective disease-modifying therapies (DMTs) for MS. FDA-approved treatments include Tysabri (natalizumab), Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), and Kesimpta (ofatumumab).

ONC201 (dordaviprone) displayed “well tolerated and durable and clinically meaningful efficacy in Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.”

A new study points to disparities for patients in respiratory failure, which can have dire consequences. The lead researchers talk about the implications.

FDA has expanded the indication for Biktarvy for those with resistant HIV, granted full approval to Rybrevant and approved Simlandi, the third interchangeable Humira biosimilar. The regulatory agency has also set action dates for sxatilimab in graft-versus-host disease, tislelizumab in stomach cancer and a second indication for Epkinly.

The company has confirmed that group representing itself as ALPHV/Blackcat, a ransomware-as-service criminal group known to cybersecurity experts, is behind the cyberattack on the pharmacy claims processor owned by UnitedHealth.

In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.

The results of this week’s poll about the recent Change Healthcare Cyberattack.

A total of 37 payers and providers have now signed on.

In this first part of a video series, Susan Cantrell, CEO of AMCP, discussed root causes of high drug prices, its impact on underserved communities and Medicare price negotiation, emphasizing AMCP's actions and the role of decreasing drug prices for equity.

Results of the evaluations will inform recommendations to payers and providers about whether and how to adopt these technologies.

One of the nation’s largest not for profit Medicare Advantage plans, SCAN Health Plan, is the first to use the feature.

Adolescent uptake levels of PrEP are low among adolescents ages 16-24 years old.

How health plans and self-insured employers coped with the huge number of prescriptions for weight loss. It started with off-label Ozempic (semaglutide) and now there’s FDA-approved Wegovy (semaglutide) and Zepbound (tirzepatide).

Some changes sparked debate among groups.

The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.

Biktarvy can now be used to treat people with HIV who have a known or suspected M184V/I mutation, a common form of treatment resistance.

High costs and prior authorization impact beneficiaries’ ability to access care. Some said they had to wait more than a month to see a doctor.

Participation in the program will not be a prerequisite for GLP-1 prescriptions.

Share your view about the Change Healthcare cyberattack.